One doctor is losing her lunch over a bizarre ad in the window of a new pizza-bagel joint in Midtown that encourages people ...

The popularity of Novo Nordisk's Ozempic and Wegovy has attracted competitors and created supply constraints. Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III ...

Novo Nordisk's (NYSE: NVO) is famous and celebrated for its cutting-edge obesity medication. Its U.S.-traded American depositary receipts (ADRs) saw their price slump by more than 2% following the ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it’s ...

German software developer SAP SE unseated Danish weight-loss drug maker Novo Nordisk A/S as Europe’s most-valuable public company. Shares of SAP, which have surged as the Walldorf, Germany-based ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Watch the video above to see the full episode of Catalysts from March 5, 2025. To watch more expert insights and analysis on ...